A phase I clinical study showed that IL-6 induced C-reactive protein and IgE levels, and had a suppressive effect on NK and lymphokine-activated killer activity in patients with advanced pancreatic cancer and colon cancer (134). Here, IL6 is linked to pancreatic neoplasm.